Opendata, web and dolomites


A diagnostics platform for dengue fever and mosquito-borne diseases

Total Cost €


EC-Contrib. €






Project "COMBO" data sheet

The following table provides information about the project.


Organization address
postcode: 2100
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Denmark [DK]
 Project website
 Total cost 2˙768˙171 €
 EC max contribution 1˙927˙219 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-2
 Funding Scheme SME-2
 Starting year 2018
 Duration (year-month-day) from 2018-05-01   to  2020-07-31


Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    BLUSENSE DIAGNOSTICS APS DK (KOBENHAVN) coordinator 1˙927˙219.00


 Project objective

BluSense Diagnostics has developed an innovative nanotechnology-based point-of-care blood testing platform for detecting dengue fever. With a single drop of blood, we can within minutes and with very high accuracy, test whether patients have been infected with dengue fever. The technology will be a major step forward in the treatment of dengue in areas around the world, where dengue is a serious threat. In 2016, more than 330m people were tested positive for dengue, and the number is growing. Our first dengue diagnostic blood-test will be ready for sales in Q2 2018.

The overall objective of the project is to enable BluSense to move from a single and narrow product (ViroTrack Dengue Acute) produced in low-volumes, to a full diagnostic dengue platform (Virotrack Dengue Combo) produced on a high-throughput automated line, and to facilitate the market entry with pre-sales activities in terms of e.g. local regulatory approval and training.

With the Virotrack Dengue Combo platform we can not only diagnose if patients are infected with dengue, but also test the severity of the infection. Hence is becomes much easier to advice the right treatment.

Beyond this project, the aim is to further develop the Virotrack Dengue Combo platform into a generic infectious diseases platform.

If the project is successful, Virotrack Dengue Combo can be launched in the market right after the 24-month project period, mid 2020. We furthermore aim at going break-even in 2021 and at that time employ 53 full-time employees, up from approx. 30 today.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "COMBO" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email ( and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "COMBO" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Dyme (2019)

Dyme gives its users complete control over their financial situation. The Dyme application provides insight into users’ spending and subscriptions, and lets users cancel, negotiate, or switch any cont

Read More  

DeltaQon (2019)

IOT and cloud computing for online medical analysis service platform

Read More  

C-Air (2018)

An innovative, reliable, lifesaving industrial air purification system that contains, cleans, and purifies air contaminated by toxic gases.

Read More